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Cost-effectiveness in the contemporary management
of critical limb ischemia with tissue loss
Neal R. Barshes, MD, MPH,a James D. Chambers, PhD, MPharm, MSc,b Joshua Cohen, PhD,b and
Michael Belkin, MD,c on behalf of the Model To Optimize Healthcare Value in Ischemic Extremities 1
(MOVIE) Study Collaborators,* Houston, Tex; and Boston, Mass
Background:The care of patients with critical limb ischemia (CLI) and tissue loss is notoriously challenging and expensive.We
evaluated the cost-effectiveness of various management strategies to identify those that would optimize value to patients.
Methods:AprobabilisticMarkovmodelwas used to create a detailed simulationof patient-oriented outcomes, including clinical
events, wound healing, functional outcomes, and quality-adjusted life-years (QALYs) after various management strategies in
a CLI patient cohort during a 10-year period. Direct and indirect cost estimates for these strategies were obtained using
transition cost-accountingmethodology. Incremental cost-effectiveness ratios (ICERs), in 2009U.S. dollars perQALYs,were
calculated compared with the most conservative management strategy of local wound care with amputation as needed.
Results:With an ICER of $47,735/QALY, an initial surgical bypass with subsequent endovascular revision(s) as needed
was the most cost-effective alternative to local wound care alone. Endovascular-first management strategies achieved
comparable clinical outcomes but at higher cost (ICERs >$101,702/QALY); however, endovascular management did
become cost-effective when the initial foot wound closure rate was >37% or when procedural costs were decreased by
>42%. Primary amputation was dominated (less effectiveness and more costly than wound care alone).
Conclusions: Contemporary clinical effectiveness and cost estimates show an initial surgical bypass is the most cost-
effective alternative to local wound care alone for CLI with tissue loss and can be supported even in a cost-averse health
care environment. (J Vasc Surg 2012;56:1015-24.)
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fGiven the unsustainable rate of growth of U.S. health
care costs and the increasingly important effect it is having
on the overall U.S. economy,1 ensuring the provision of
cost-effective care stands among the foremost priorities for
U.S. clinicians.2,3 This priority should be especially poi-
gnant for vascular surgeons who care for patients with
critical limb ischemia (CLI) and tissue loss, for several
reasons. First, care for these patients is costly, laborious,
and will not infrequently result in limb loss despite intensive
efforts to avoid it.4 Second, the U.S. population is increas-
ingly elderly and/or diabetic, two characteristics that are
strongly associated with CLI.5 Finally, management of the
ischemic limb is done in the context of systemic comorbidi-
From the Division of Vascular Surgery and Endovascular Therapy, Michael
E. DeBakey Department of Surgery, Baylor College of Medicine, Hous-
tona; the Center for the Evaluation of Value and Risk in Health, Institute
for Clinical Research and Health Policy Studies, Tufts Medical Center,
Bostonb; and the Division of Vascular and Endovascular Surgery, Depart-
ment of Surgery, Brigham and Women’s Hospital, Boston.c
*A list of the MOVIE collaborators can be found in Appendix A.
Author conflict of interest: none.
Presented at the Thirty-eighth Annual Meeting of the New England Society
for Vascular Surgery, Providence, RI, September 16-18, 2011.
Additional material for this article may be found online at www.jvascsurg.org.
Correspondence: Michael Belkin, MD, Professor and Chief, Division of
Vascular and Endovascular Surgery, Department of Surgery, Brigham and
Women’s Hospital, 75 Francis St, Boston, MA 02215 (e-mail:
mbelkin@partners.or).
The editors and reviewers of this article have no relevant financial relation-
ships to disclose per the JVS policy that requires reviewers to decline
review of any manuscript for which they may have a conflict of interest.
0741-5214/$36.00
Copyright © 2012 Published by Elsevier Inc. on behalf of the Society fort
Vascular Surgery.
http://dx.doi.org/10.1016/j.jvs.2012.02.069ies that typically limit survival of the CLI patient popula-
ion to 50% at 5 years.6
The challenges present in the management of patients
ith CLI may lead to pessimism about the utility of limb
alvage efforts. Even some within the field of vascular
urgery have wondered whether aggressive revasculariza-
ion and efforts to save the limb are worthwhile and
hether primary amputation would be a better option for
any patients.7-9 To date, however, any statement on the
elative cost-effectiveness of various CLI management
trategies would have been conjecture, because no formal
ost-effectiveness analysis comparing revascularization
trategies has been published in the past 15 years.10
In this report, we describe our efforts to quantify the
ost-effectiveness of various contemporary CLI manage-
ent strategies. Specifically, the primary goal was to esti-
ate incremental cost-effectiveness ratios for competing
anagement strategies for CLI with tissue loss. We also
ought to further understand the relationship between
osts and effectiveness and to create a robust computer
odel to accurately simulate the 10-year outcomes of CLI
anagement.
ETHODS
Management strategies. The primary objective of
his study was to compare the long-term costs and effec-
iveness of various management strategies used in contem-
orary clinical practice in the U.S. for previously ambula-
ory, independently living patients presenting with CLI and
issue loss in the context of a salvageable foot (ie, Ruther-
ord category 5 limb ischemia11). The comparison assumed
he availability of vein (saphenous or other) for conduit and
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October 20121016 Barshes et alanatomy that could be treated with surgical bypass or an
endovascular intervention. A computerized Markov model
simulation quantified the cost-effectiveness of these man-
agement strategies.12-14 Six contemporary strategies for
managing CLI with tissue loss were evaluated (Table I),
and their respective benefits were categorized according to
the patient-oriented outcomes of ambulatory status, inde-
pendent living status, and state of wound healing (Fig 1).
Strategy 1: A conservative strategy of local wound care
with major amputation was used as the baseline comparator
strategy. Patients were subject to the possibility of sponta-
neous wound healing, with or without recurrence, the
possibility of requiring major amputation, and the possibil-
ity of death due to coronary, cerebrovascular, or other
causes.
Strategy 2: Patients underwent primary amputation at
the initiation of the model and were subject to the possi-
bility of impaired stump wound healing and the possibility
of death (periprocedural or other).
The remaining four limb salvage strategies began with
an index revascularization procedure, followed by wound
care, and the possibility of requiring reintervention to
maintain or restore patency, the possibility of requiring
major amputation, and the possibility of periprocedural
death or death from another cause (Fig 1).
Strategy 3: Patients underwent an initial infrainguinal
surgical bypass with a vein conduit and were then subject to
the need for up to five additional surgical procedures to
maintain or restore patency.
Strategy 4: Patients underwent an initial infrainguinal
surgical bypass with a vein conduit and were then subject to
the need for up to five endovascular interventions to main-
tain or restore patency of the vein graft.
Strategy 5: Patients underwent an initial endovascular
intervention andwere then subject to the need for up to five
Table I. Summary of the strategies modeled
Strategy Management summary Init
1 Local wound care Local w
2 Primary amputation Major
3 Bypass with surgical revision(s) Surgica
4 Bypass with endovascular
revisions
Surgica
5 Purely endovascular Endova
6 Endovascular, bypass for failure Endova
CLI, Critical limb ischemia.additional endovascular interventions. nStrategy 6: Patients underwent an initial endovascular
ntervention; if this failed, a surgical bypass was performed
nd up to four additional surgical procedures tomaintain or
estore patency.
The base-case scenario assumed that no foot wound in
hese patients was closed during the initial hospitalization.
Estimates of clinical and utility parameters. The
election of estimates for the clinical event and utility
arameters of this model has been previously described.5 In
rief, previously published limb salvage literature was com-
rehensively reviewed, with emphasis given to studies spe-
ifically focused on clinical trials and observational studies
f high methodologic quality that focused on patients with
LI and tissue loss. Uncertainty in the estimates of various
arameters was accounted for using a probabilistic model
tructure; thus, the parameters used in a given simulation
aried randomly within a predetermined distribution that
as thought to best represent the degree of uncertainty
ssociated with various parameter estimates. Additional
eterministic sensitivity analyses were used to vary prese-
ected parameters over a range of possible values to better
nderstand the relationship between parameters and to
dentify threshold parameter values beyond which certain
tudy findings would change. Selected parameters used in
he model are presented in Table II.
Estimates of cost parameters. Consistent with recom-
ended guidelines,14 a societal perspective was considered in
he base-case analysis. Accordingly, inpatient and outpatient
osts accumulated by patients with Rutherford 5 CLI were
onsidered. A thorough literature review revealed that most
ublications reporting inpatient cost estimates were of insuf-
cient quality for contemporary cost-effectiveness evaluation
ecause they were published10 years ago or were based on
dministrative/claims databases, which do provide data on
arge numbers of patients but provide payments or charges,
tervention
Subsequent interventions other than
wound care
care alone Major amputation as indicated
tation None
ass Up to five surgical procedures as needed
to maintain or restore patency; major
amputation as indicated
ass Up to five endovascular interventions as
needed to maintain or restore patency;
major amputation as indicated
r intervention Up to five additional endovascular
interventions as needed to maintain or
restore patency; major amputation as
indicated
r intervention Surgical bypass for failure of
endovascular intervention to alleviate
CLI; up to four additional surgical
procedures to maintain or restore
patency; major amputation as
indicatedial in
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Volume 56, Number 4 Barshes et al 1017populations.15 We therefore endeavored to obtain accurate
estimates of the costs of managing patients with Rutherford 5
CLI that were representative of contemporary vascular sur-
gery practice in U.S. medical centers through a patient-level
transaction cost-accounting system (see Appendix B [online
only] for details).
Estimates of relevant outpatient costs were obtained
from the published literature (Table II).5 In brief, impor-
tant outpatient costs included the cost of wound care, limb
prosthesis purchase and maintenance, short-term rehabili-
tation stays in a nursing facility, and long-term stays in
nursing homes. We did not include the effect of lost work-
days for patients because the advanced age and degree of
baseline morbidity associated with CLI typically precludes
employment in these patients.
A computer simulation was used to create a probabilis-
tic Markov model that recreated the above-described clin-
ical events, patient-oriented outcomes, utilities, and costs
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Fig 1. Schematic diagram demonstrates an overview of
simulation for critical limb ischemia (CLI) managementresulting from various management strategies. Simulations tor each management strategy were performed for 1000
ypothetical cohorts, each with 1000 patients. A 10-year
ime horizon was chosen with Markov cycles of 1 year in
uration. All modeling and analysis was performed using
xcel 2003 software (Microsoft Corp, Redmond, Wash)
ith additional programming in Visual Basic for Applica-
ion (Microsoft Corp). Reported clinical or utility values
epresent the median value of the 1000 simulations.
All cost values reported are in 2009 U.S. dollars (USD)
nd represent amedian value, unless otherwise noted.Utilities
nd cost values were discounted at the recommended 3.5%
nnual rate.16 Cost-effectiveness was quantified using incre-
ental cost-effectiveness ratios (ICERs) in USD per quality-
djusted life-years (QALY) and cost-effectiveness acceptability
urves.
To explore other outcomes that may provide meaning-
ul value to patients not expressed in QALYs, two alterna-
ive measures of cost-effectiveness were also considered: (1)
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October 20121018 Barshes et alosts of limb salvage efforts to the duration of time for
hich the limb is salvaged; and (2) the cost per functional
imb-year, calculated as the ratio of costs of providing any
unctioning limb—whether that be through salvage of the
utogenous limb or through postamputation ambulation
sing a limb prosthesis—to the duration of time during
hich the patient has a functional autogenous or prosthetic
imb.
ESULTS
Base-case scenario: clinical outcomes and health
tilities. The strategy of local wound care (strategy 1)
esulted in expectedly poor limb salvage rates of 27.0% at 5
ears and 9.8% at 10 years. Of the patients surviving at 5
ears, 73.9% had undergone a major amputation, 13.2%
ad a persistent or recurrent ulcer or foot wound, and
2.9% had healed. At 5 and 10 years, 18.2% and 22.4% of
atients, respectively, lived in a nursing home. This strategy
roduced a mean of 2.287 QALYs per patient.
Primary amputation (strategy 2) obviously resulted in
o limb salvage. The percentage of surviving patients that
emained ambulatory with a prosthetic limb was 72% at 5
nd 10 years, and overall 24.6% of patients remained am-
ulatory at 5 and 10 years. The strategy of primary ampu-
ation produced a mean of 2.178 QALYs per patient.
Strategies 3 and 4, which featured an initial surgical by-
ass, both resulted in limb salvage rates of 79.2% at 5 years and
9.9% at 10 years. Revision or reintervention was required in
6.8% of patients in both groups. Of these, 76.7% underwent
ne revision, 19.0% underwent two revisions, 3.6% under-
ent three revisions, and 0.06% underwent four. At 5 and 10
ears, 92% and 90% of living patients remained ambulatory,
nd 6.1% and 8.4% of patients lived in nursing homes. Both
trategies produced a mean of 2.556 QALYs per patient.
Strategies 5 and 6, which featured an initial endovascular
ntervention, resulted in limb salvage rates of 79.4% to 79.6%
t 5 years and 70.0% at 10 years. In strategy 5, which was
urely endovascular, a repeat endovascular intervention was
equired in 25.6% of patients, comprising one repeat interven-
ion in 78.3%, two repeat interventions in 17.1%, three repeat
nterventions in 3.7%, and four repeat interventions in 0.9%.
n strategy 6, endovascular with bypass for failure, 25.6% of
atients underwent surgical revision. As with surgical bypass
trategies, the percentage of surviving patients that remained
able II. Continued.
arameter Point estimate Rangeb
imb prosthesis
Initial purchase, $ 10,000 6,057-14,573
Yearly maintenance, $ 750 513-995
See the review by Barshes et al5 for more details.
The full range of values used in the probabilistic model was determined by
arious distributions which included beta, gamma, and triangular. The
anges listed here are the 95% confidence level equivalent for clinical event
robabilities and utilities and the actual range (minimum and maximum) for
ost values.Table II. Important parameters included in the modela
Parameter Point estimate Rangeb
Clinical events
Annual (baseline) mortality, % 11.70 9.3-14.1
Excess mortality rate associated
with
Major amputation, % 3.90 2.1-5.7
Surgical bypass, % 2.60 1.4-3.8
Endovascular intervention, % 2.60 1.4-3.8
Annual rate of major amputation
during year 1 after
Local wound care, % 38.00 27.9-48.1
Surgical bypass, % 10.80 8.4-13.2
Endovascular intervention, % 12.20 6.9-17.5
Annual rate of major amputation
during years 2-10 after
Local wound care, % 38.00 27.9-48.1
Surgical bypass, % 2.60 2.0-3.0
Endovascular intervention, % 2.60 2.0-3.0
Wound healing at 1 year after
Local wound care, % 41.00 24.8-57.2
Surgical bypass, % 95.00 90.0-100.0
Endovascular intervention, % 60.30 53.6-67.0
Probability of reintervention
(endovascular or surgical)
after
Surgical bypass, % 22.70 20.5-24.9
Endovascular intervention, % 26.00 23.8-28.2
Probability of initial discharge to
rehabilitation facility after
Local wound care, % 0 0
Major amputation, % 100 100
Surgical bypass, % 28.70 26.3-31.1
Endovascular intervention, % 28.70 26.3-31.1
Probability of ambulation after
Major amputation, % 55.50 52.4-58.6
Surgical bypass, % 97.10 95.5-98.7
Endovascular intervention, % 97.10 95.5-98.7
Probability of living independently
after discharge
Surgical bypass, % 98.60 97.7-99.5
Endovascular intervention, % 98.60 97.7-99.5
Major amputation, % 92.00 86.5-97.5
Utilities associated with wounds
Unhealed (persistent/recurrent)
foot wound or unhealed
amputation stump wound
after
Local wound care, % 0.42 0.28-0.52
Primary amputation, % 0.48 0.30-0.58
Surgical bypass, % 0.5 0.57-0.67
Endovascular intervention, % 0.5 0.59-0.69
Healed wound after
Local wound care, % 0.64 0.59-0.69
Primary amputation, % 0.54 0.32-0.65
Surgical bypass, % 0.62 0.54-0.70
Endovascular intervention, % 0.62 0.54-0.70
Outpatient costs
Local wound care, per year, $ 21,029 19,036-25,715
Inpatient rehabilitation and/or
home health nursing, $ 12,048 $1364-44,895
Residence in a nursing home, permbulatory in strategies 5 and 6was 92% and 90% at 5 and 10
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Volume 56, Number 4 Barshes et al 1019years, respectively, and 6.5% and 8.7%, respectively, of patients
lived in a nursing home. Strategy 5 produced 2.448 QALYs
and strategy 6 produced 2.472 QALYs.
Patient survival was similar across all models, with mean
survival rates of 51.4% for primary amputation, 51.5% and
51.6% for endovascular-first and surgery-first strategies, and
52.3% at 5 years. The 10-year survival rate was 27.4% to
28.0%.
Costs and cost-effectiveness. Themedian costs of the
hospitalizations associated with various index procedures,
obtained from the single-center review with activity-based
cost allocation,17 were $44,634 for infrainguinal bypass,
$26,509 for endovascular intervention, $28,701 for major
amputation, $28,039 for surgical revision of a vein graft,
$13,137 for endovascular intervention of a vein graft, and
$17,751 for minor amputation and foot debridement.
These costs were incorporated into the simulationmodel,
Table III. The costs, benefits, and incremental cost-effect
strategies for Rutherford category 5 critical limb ischemia (
Strategy Management
Cost, $
(2009 used)
Strategy 1 Local wound care 68,736
Strategy 4 Bypass with endovascular revisions 81,920
Strategy 3 Bypass with surgical revisions 84,961
Strategy 6 Endovascular, bypass for failure 88,306
Strategy 5 Purely endovascular 89,040
Strategy 2 Primary amputation 78,958
QALYs, Quality adjusted life-years.
Fig 2. The annual costs per living patient are demonstr
management strategies: (A) strategy 1 (local wound care)
bypass with surgical revision); (D) strategy 4 (surgical
endovascular intervention); and (F) strategy 6 (endovascwhich then estimated the long-term (10-year) costs associated aith various strategies (Table III). The strategy of local
ound care alone (strategy 1) was associated with the lowest
otal cost, with a mean total 10-year cost of $68,736. The
ndovascular-first strategies had the highest costs, at $89,040
or strategy 5 and $88,306 for strategy 6. The long-term cost
ssociated with primary amputation (strategy 2) was $78,958
nd was comparable to costs for the surgery-first strategies of
84,961 for strategy 3 and $81,920 for strategy 4.
Fig 2 demonstrates the annual per capita costs for all six
trategies, showing that localwound care (strategy 1; Fig 2,A)
ad the lowest initial cost of $24,008 during year 1, but costs
uring subsequent years were $14,354 to $16,920 per year.
n contrast, strategies 3 and4 (Fig 2,C andD) had the highest
nitial costs—$71,976 and $69,553, respectively, during year
—but the lowest subsequent annual costs (range, $3485-
4901). The year-1 costs of $55,445 and $59,247 for the
ndovascular-first strategies (5 and 6), respectively (Fig 2, E
ss ratios (ICERs) of various contemporary management
)
efit Compared with strategy 1
ICER, $LYs) Incremental cost, $ Incremental benefit
80 . . . . . . . . .
56 13,184 0.276 47,738
56 16,225 0.276 58,749
72 19,570 0.192 101,702
48 20,304 0.168 121,010
78 10,222 0.102 Dominated
uring the 10-year interval after the initiation of various
strategy 2 (primary amputation); (C) strategy 3 (surgical
ss with endovascular revision); (E) strategy 5 (purely
intervention, surgical bypass for failure).ivene
CLI
Ben
(QA
2.2
2.5
2.5
2.4
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2.1ated d
; (B)
bypand F), were somewhat less than the costs of the surgery-first
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October 20121020 Barshes et alstrategies (3 and 4) but had higher subsequent annual costs of
$7987 to $9762 for strategy 5 and $6956 to $9740 for
strategy 6 due to the higher rates of reintervention and con-
tinuing wound care needs. Primary amputation (strategy 2;
Fig. 2, B) had a year-1 cost of $51,117—intermediate be-
tween surgical bypass and local wound care—but the subse-
quent annual costs (range, $14,354-$16,920) were higher
than those of the endovascular-first strategies.
Considering long-term costs and benefits in the estima-
tion of ICERs, we found that bypass with endovascular revi-
sions (strategy 4)was associatedwith an ICERof $47,738 and
was the most cost-effective alternative to local wound care
alone. Fig. 3 is a scatterplot, or cost-effectiveness plane, that
displays the ICERs of each of the 1000 trials. As illustrated,
surgical bypass with endovascular revision (strategy 4) pro-
vided incremental benefit (ie, more QALYs) vs local wound
care. This strategy actually provided cost savings (higher ben-
efits at lower costs) in 10.8% of trials. Bypass with surgical
revision (strategy 3) yielded an ICERof $58,749, comparable
to that of bypass with endovascular revision (strategy 4). The
ICERs associated with the two endovascular-first strategies
(strategies 5 and 6) were higher, at $121,010 and $101,702,
respectively. Finally, primary amputation was dominated; that
is, it was both more costly and provided less benefit than local
wound care.
A cost-effectiveness acceptability curve demonstrating
the relationship between the willingness-to-pay threshold
and the probability that various management strategies are
cost-effective is presented in Fig 4. The probability of
surgical bypass with endovascular revisions (strategy 4)
Fig 3. The incremental costs (in 2009 U.S. dollars)
demonstrated for strategy 4 (surgical bypass with endov
with amputation as indicated).being a more cost-effective approach than conservative ianagement (strategy 1) was 25.9% at a willingness-to-pay
hreshold of $25,000/QALY, 48.7% at a threshold of
50,000/QALY, 75.7% at a threshold of $100,000/
ALY, and 90.2% at threshold of $200,000/QALY.
Alternative end points. The findings were largely
imilar when the two alternative measures of benefit or
value” to patients were considered. First, compared with
ocal wound care alone, the costs per year of limb preserva-
ion were lowest for the surgery-first strategies 3 and 4
$8640 and $7021/limb-year, respectively) and slightly
igher for endovascular-first strategies 5 and 6 ($10,752
nd $10,399/limb-year, respectively). Similarly, the cost
er functional limb-year (ie, ambulation on a functioning
imb after limb preservation or on a limb prosthesis after
ajor amputation) was lower for the surgery-first strategies
and 4 ($6934 and $5634/functioning limb-year, respec-
ively) than the endovascular-first strategies 5 and 6 ($8660
nd $8350, respectively) compared with local wound care
lone. Primary amputation cost $15,527/functional limb-
ear compared with local wound care and was the highest
ost of all management strategies assessed.
Deterministic sensitivity analyses. Several determin-
stic sensitivity analyses were performed. First, the effects of
osts related to endovascular and surgical procedures were
xamined.With all other parameters remaining unchanged,
he ICER of the endovascular-first strategies did not de-
rease below the ICER of the bypass-first strategies until
ndovascular procedural costs were decreased by 42%;
pecifically, from $26,509 to $15,640. We also consid-
red the possibility that the frequency of hospitalization
incremental benefits (quality-adjusted life-years) are
r revision) compared with strategy 1 (local wound careand
asculancreased more after surgical bypass than after the other
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Volume 56, Number 4 Barshes et al 1021strategies by simulating an additional $20,000 of accumu-
lated inpatient hospital costs during the first year after
surgical bypass. Even with this additional cost, bypass with
endovascular revision (strategy 4) remained the most cost-
effective alternative to local wound care, but the corre-
sponding ICER increased to $119,060/QALY.
The wide range of reported reintervention rates after
endovascular intervention5 suggested uncertainty about
the estimates for this parameter, and a conservative point
estimate of 26% was used in the base-case model. To
explore the effect of an increased reintervention rate after
endovascular intervention, the effect of a 50% reinterven-
tion rate was examined. This increased the ICER of a purely
endovascular intervention (strategy 5) to $125,583 and the
ICER of endovascular intervention with bypass for failure
(strategy 6) to $104,481.
The base-case model included the conservative as-
sumption of a 0% wound closure rate during the index
hospitalization. As might be expected, the ICER of all the
limb salvage strategies decreased as the wound closure rate
increased. In fact, the ICER of the endovascular-first strat-
egies decreased at a faster rate than the ICER of the
surgery-first strategies. As a result, the purely endovascular
intervention (strategy 5) became a more cost-effective al-
ternative to local wound care than surgery with endovascu-
lar revisions (strategy 4) once the initial wound closure rate
increased 37%. The purely endovascular intervention be-
came cost saving (ie, both more beneficial and less costly)
Fig 4. Cost-effectiveness acceptability curves are show
compared with strategy 1 (local wound care). The probab
being a cost-effective alternative increases as the willingn
per quality-adjusted life-year.than local wound care once the initial wound closure rate teached 51%, and surgical bypass with endovascular revi-
ions became cost saving once the initial wound closure rate
ncreased 71%.
Finally, cost perspective was changed to model the
hird-party payer perspective by considering only inpatient
osts, interim stays in rehabilitation facilities, and purchase
nd maintenance costs for a limb prosthesis. The costs of
ound care and residence in a nursing home were ex-
luded. In this scenario, the ICERs of the bypass-first
trategies increased ($136,101 for strategy 3 and $125,237
or strategy 4) and became slightly higher than those of the
ndovascular-first strategies ($117,182 for strategy 5 and
123,348 for strategy 6). Primary amputation remained
ominated.
ISCUSSION
For the past 2 decades, U.S. clinicians have driven
vidence-based care for patients with vascular diseases
hrough the collaborative performance of high-quality
andomized, controlled clinical trials18-22 and multidis-
iplinary consensus statements on the management of
ascular diseases.23-26 More recently, U.S. clinicians who
reat vascular disease have advocated for patient safety
hrough the formation of regional quality-improvement
nitiatives and the analysis of risk-adjusted outcomes
ata.27-29 The most pressing issue currently facing U.S.
linicians and U.S. health care in general is unsustainable
ncreases in the per-capita costs of health care.1,30 Thus,
r critical limb ischemia (CLI) management strategies
f strategy 4 (surgical bypass with endovascular revision)
-pay threshold in U.S. dollars (USD) surpasses $39,255n fo
ility o
ess-tohe foremost challenge for vascular clinicians is to find
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outcomes while minimizing monetary costs—in other
words, optimizing the cost-effectiveness and “value” of
the health care provided to patients.2
This study suggests that surgical bypass with endovas-
cular revision(s) as needed is the most cost-effective alter-
native to local wound care for previously ambulatory, inde-
pendently living patients who present with CLI and tissue
loss. With an ICER of $47,738, this management strategy
is well within the range of cost-effectiveness values tradi-
tionally accepted to represent an efficient use of resources in
theU.S. ($50,000-$120,000/QALY)3,31,32 and not far off
the much more stringent £20,000/QALY ($33,000/
QALY) threshold suggested by the United Kingdom’s
National Institute for Health and Clinical Excellence for
being considered cost-effective.33 Endovascular-first inter-
vention strategies did not prove to be cost-effective for
patients presenting with CLI and tissue loss in our base-
case scenario, but several possible scenarios (including a
reduction of endovascular procedure costs and improve-
ment in the postintervention wound healing rate) could
make endovascular strategies a cost-effective management
approach.
In contrast to what some authors have suggested,7-9
primary amputation does not appear to be a cost-effective
management option by standard measurements of cost per
QALY or by the alternativemeasures of cost per benefit that
we considered in this study. Indeed, primary amputation
was dominated (ie, provided fewer benefits and required
higher costs) by all of the management strategy options
considered. Although there are valid indications for pri-
mary amputation in select patients (eg, foot wounds that
cannot be salvaged or nonambulatory patients), this study
suggests that expectant management with local wound care
and major amputation as needed would be a more cost-
effective management strategy for ambulatory, indepen-
dently living patients with CLI and tissue loss.
This study has helped to identify certain cost drivers,
which, if effectively targeted, may provide the opportu-
nity to further improve the cost-effectiveness of limb
salvage efforts. As mentioned, one such cost driver is the
rate of wound healing after revascularization. The devel-
opment of reliable strategies, techniques, or adjuncts to
improve the wound healing rate after revascularization
or to allow for the early closure of foot wounds34 would
improve the cost-effectiveness of all limb salvage and
revascularization strategies, possibly to the point that
these strategies would be dominant; that is, associated
with improved outcomes and lower costs compared with
local wound care alone.
Procedural costs may be another such cost driver. As
the deterministic sensitivity analyses demonstrated, the
cost-effectiveness of the various management strategies
may vary somewhat in health care environments that have
different absolute and relative costs but would be unlikely
to change the ranking without large differences in these
procedural costs. Nonetheless, similar analyses should be
repeated across a variety of cost structures and operating Invironments, and each center should examine its own
osts before generalizing the results of this study to its own
ractice.
Another important finding that merits discussion is
he discrepancy between estimated ICERs of the limb
alvage strategies when considering payer and societal
erspectives. The societal perspective is all-encompass-
ng and includes costs associated with a management
trategy or health technology, regardless of the payer.
his perspective is recommended in cost-effectiveness
nalysis because it is thought to be a more accurate
epresentation of the true costs of health care.14 The
ayer perspective, in contrast, considers only costs that
ight be paid by a particular payer. In this study, we
erformed a sensitivity analysis that simulated the payer
erspective of Medicare part A or certain other nongov-
rnmental third-party payers that might pay the costs of
npatient care, interim stays in rehabilitation facilities,
nd limb prostheses but not the costs of outpatient
ound care and nursing home care. This change in payer
erspective alone led to purely endovascular intervention
strategy 5) appearing to have cost savings compared
ith local wound care alone. The costs of outpatient
ound care and nursing home costs would have to be
orne by some payer—in many circumstances, the pa-
ient as an individual through out-of-pocket expenses or
he taxpayers as a society—so the conclusions drawn
rom this payer perspective are clearly not the best rep-
esentation of “value.” Yet, this provides a clear example
f how imperfect alignment between societal, payer, and
atient interests may reinforce perverse incentives rather
han optimizing the “value” of health care.2 So, al-
hough deterministic sensitivity analyses from the insti-
utional perspective are recommended, we strongly em-
hasize the recommended use of the societal payer
erspective for the base-case scenario of future cost-
ffectiveness analyses in vascular surgery.14
The high degree of consistency between the clinical
utcomes projected by the simulation model in this
tudy and studies upon which the projections were based
nd others upon which it was not directly based suggest
he model has internal and external validity. Specifically,
-year limb salvage rates that are 79% and equivalent for
ndovascular and surgical strategies are comparable to
he results of the Bypass versus Angioplasty in Severe
schaemia of the Leg (BASIL) trial and several high-
uality observational studies that report long-term out-
omes,19,35-37 and projected 5-year survival rates of 51%
o 52% for the various strategies are consistent with
linical trials and large clinical studies.18,36-38 Although
here are plentiful data on limb salvage and patient
urvival rates in the published literature, for example,
uch less data are available for health utilities before or
fter limb salvage efforts. Uncertainty can be accounted
or in the model to some degree, but the potential for
ncertainty or inaccuracy to nevertheless lead to biased
CER estimates does remain.
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This study suggests that although endovascular-first
and surgery-first strategies can both achieve comparable
long-term limb salvage rates, surgical bypass (especially
with endovascular revisions as needed) is the most cost-
effective alternative to local wound care alone for the
management of CLI with tissue loss. Primary amputation
is as costly as bypass, yet it provides less benefit than local
wound care and is thus dominated by these other man-
agement strategies. Vascular clinicians should weigh
clinical benefits as well as costs in choosing management
strategies, because providing cost-effective care is in the
interest of not only patients and payers but also health
care providers.
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Methodology for obtaining cost estimates. To ob-
tain inpatient hospitalization cost estimates, we first
identified all patients undergoing index interventions for
critical limb ischemia (CLI) with tissue loss, specifically,
nonhealing ulcers, dry gangrene of toe(s) or foot, or
nonhealing wounds after minor amputation, in the con-
text of a salvageable foot (ie, Rutherford category 5 limb
ischemia) through a comprehensive search of the oper-
ating room and endovascular suite registries at the
Brigham and Women’s Hospital, starting on January 1,
2009, and proceeding forward chronologically. Patients
were included for analysis if the procedure performed
included any of the following major interventions: (1) an
initial infrainguinal surgical bypass with vein graft con-
duit, (2) an initial endovascular intervention (including an-
gioplasty and selective stenting†) for infrainguinal arterial oc-
clusive disease, or (3) primary major amputation, including
amputations below, through or above the knee.
Once these patients were identified, the total costs
(direct plus indirect costs‡) of their full inpatient hospital
†In contrast to direct costs (costs that can be directly linked to an individual
patient or particular unit of production), indirect costs include “over-
head” and capital costs, which are more difficult to allocate among
patients. Examples of such costs include hospital administration, house-
keeping, the costs associated with the use of an operating room for an
interval of time.‡In the cost data from our institution, the total direct and indirect proce-
dural costs for patients undergoing endovascular intervention representedtays were obtained and categorized by index intervention.
hese direct and indirect costs2 were calculated using our
nstitution’s transition cost accounting system (Eclipsys
olutions Corp, Boca Raton, Fla) to obtain individual
atient-level activity-based estimates17 of the total cost for
npatient hospitalizations. A median cost and cost distribu-
ion was then obtained based on the sample of patients
ndergoing various interventions.
In a similar fashion, the costs of the inpatient hospital-
zations associated with the following secondary proce-
ures were also calculated: (1) endovascular revision of a
hreatened, failing, or failed bypass graft, including percu-
aneous thrombectomy, angioplasty, and stenting; (2)
urgical revision of a threatened, failing, or failed bypass
raft, including thrombectomy and revision of the by-
ass graft; or (3) foot wound care-associated procedures,
ncluding debridement, skin grafting, and any amputa-
ions limited to the forefoot or midfoot such as toe
mputations or transmetatarsal amputations. A total of
1,206 cost items associated with 86 patients with Ruth-
rford category 5 limb ischemia were reviewed and used
n cost calculations. The cost data were obtained under
he approval of Brigham and Women’s Hospital/Part-
ers Human Research Committee Institutional Review
oard (Protocol #2010-P-002227/1).
44% of the total cost of hospitalization, and the cost of stents represented
just 5.6% of the total cost of hospitalization. Atherectomy devices, cryo-
plasty balloons, and reentry devices were not used at this center.
